Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Sold by Trexquant Investment LP

Trexquant Investment LP lessened its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 18.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 227,598 shares of the company's stock after selling 51,759 shares during the quarter. Trexquant Investment LP owned 0.11% of Cellebrite DI worth $5,014,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the company. Quarry LP purchased a new position in shares of Cellebrite DI during the third quarter valued at $27,000. R Squared Ltd bought a new position in shares of Cellebrite DI during the fourth quarter valued at approximately $100,000. Polen Capital Management LLC purchased a new position in Cellebrite DI during the fourth quarter valued at approximately $222,000. Victory Capital Management Inc. purchased a new position in Cellebrite DI during the fourth quarter valued at approximately $234,000. Finally, HighTower Advisors LLC bought a new position in Cellebrite DI in the fourth quarter worth approximately $274,000. 45.88% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Lake Street Capital upped their price objective on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. JPMorgan Chase & Co. increased their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $28.00 price objective on shares of Cellebrite DI in a research note on Wednesday, April 2nd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $23.43.

Remove Ads

Cellebrite DI Stock Performance

CLBT stock traded down $0.49 during trading on Thursday, reaching $18.49. The company had a trading volume of 263,910 shares, compared to its average volume of 1,394,985. The company has a market cap of $4.43 billion, a price-to-earnings ratio of -13.34, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a twelve month low of $10.25 and a twelve month high of $26.30. The firm has a 50-day simple moving average of $19.86 and a 200-day simple moving average of $19.97.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Sell-side analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.